• Lilliam Ambroggio, Jennifer A Taylor, Loni Philip Tabb, Craig J Newschaffer, Alison A Evans, and Samir S Shah.
• Department of Epidemiology and Biostatics, Drexel University, Philadelphia, PA, USA. lilliam.ambroggio@cchmc.org
• J. Pediatr. 2012 Dec 1;161(6):1097-103.

ObjectiveTo determine the comparative effectiveness of β-lactam monotherapy and β-lactam and macrolide combination therapy on clinical outcomes in the treatment of children hospitalized with community-acquired pneumonia (CAP).Study DesignThis multicenter retrospective cohort study included children aged 1-18 years who were hospitalized with CAP and received β-lactam antibiotic therapy either alone or in combination with a macrolide. Data were obtained from the Pediatric Health Information System. Associations between empiric antibiotic therapy and hospital readmission for the same episode of pneumonia were estimated using exact logistic regression. Associations between empiric antibiotic therapy and length of hospital stay were estimated using a generalized estimating equation with negative binomial distribution.ResultsThere were 20 743 patients hospitalized with CAP. Of these, 24% received β-lactam and macrolide combination therapy on admission. Compared with children who received β-lactam monotherapy, children who received β-lactam plus macrolide combination therapy were 20% less likely to stay in the hospital an additional day (adjusted relative risk 0.80; 95% CI, 0.75-0.86) but did not have a different readmission rate (relative risk 0.69; 95% CI, 0.41-1.12). An effect of combination treatment on reduced length of stay was not evident in children <6 years of age but increased with increasing age groups thereafter.ConclusionSchool-aged patients hospitalized with CAP who received β-lactam plus macrolide combination therapy have a shorter length of stay and similar rates of readmission compared with school-aged patients who receive β-lactam monotherapy.Copyright © 2012 Mosby, Inc. All rights reserved.

30 keywords...

hide…